Laboratory and instrumental criteria for assessing the persistence of primary hyperparathyroidism within the first day after surgery. Retrospective assessment of risk

Main Article Content

P.O. Lishchynski
V.O. Palamarchuk
O.P. Nechay
M.A. Urina
O.A. Tovkay
V.V. Kutz


Background. The variability of laboratory results leads to an in­depth study of the past medical history and clinical picture, as well as diagnostic procedures to detect parathyroid glands with altered functional activity. The purpose of the study was to determine the most effective methods for assessing the persistence of primary hyperparathyroidism (PHPT) in the early postoperative period and ways to prevent such a condition. Materials and methods. A retrospective review of a prospectively collected database of patients operated for PHPT has been conducted. At the preoperative stage, an ultrasound examination of the neck, along with the evaluation of ionized calcium, parathyroid hormone and blood creatinine, was performed in all patients to visualize parathyroid adenomas. Results. Between January 1, 2014 and December 31, 2018, 436 patients underwent surgery for PHPT, 408 women (93.6 %) and 28 men (6.4 %). Seven patients (1.6 %) required repeated surgery for the persistence of hyperparathyroidism, which correlates with data from foreign scientific papers. Each case is considered separately. Three patients underwent 99mTc­MIBI scan at the preoperative stage. The persistence criteria were parathyroid hormone and ionized calcium levels on the first day of the postoperative period. The average level of parathyroid hormone before surgery in these patients was 182.15 ± 31.25 pg/ml, the average level of Ca2+ — 1.44 ± 0.05 mmol/l. After performing first surgery, the level of parathyroid hormone decreased on avera­ge to 117.55 ± 20.55 pg/ml, Ca2+ — to 1.34 ± 0.05 mmol/l. It should be noted that all these patients underwent a unilateral revision of the parathyroid glands. Considering the presence of obvious laboratory signs of hyperparathyroidism persistence, additional instrumental study (contrast­enhanced computed tomography of the chest) and repeated surgery were performed in 4 patients. After repeated surgical treatment, the level of parathyroid hormone decreased on average to 40.19 ± 13.21 pg/ml, the level of Ca2+ — to 1.25 ± 0.03 mmol/l. For the control group, 80 patients were selected, they underwent successful surgical treatment for PHPT. The average level of parathyroid hormone before surgery was 206.3 ± 16.0 pg/ml, the average level of Ca2+ — 1.48 ± 0.02 mmol/l. After first operation, parathyroid hormone decreased on average to 16.67 ± 1.28 pg/ml and Ca2+ — to 1.19 ± 0.01 mmol/l. The main cause of PHPT persistence is a combination of parathyroid hyperplasia and parathyroid adenoma (4 patients (57.14 %)). Rarely, the cause of disease persistence was double parathyroid adenoma — in 2 patients (28.57 %) and true parathyroid hyperplasia — in 1 patient (14.29 %). Conclusions. Determining the level of parathyroid hormone on the first postoperative day is of critical importance after intervention for PHРT in terms of hypocalcemia or disease persistence detection, followed by determination of ionized calcium in the blood, which characterizes the effectiveness of surgical treatment. The combination of parathyroid adenoma and true parathyroid hyperplasia that was not verified at the preoperative stage by additional instrumental methods (contrast­enhanced multislice computed tomography of the neck and chest with) is the main cause of persistence of primary hyperparathyroidism. Rarely, the cause of disease persistence is double parathyroid adenoma and true parathyroid hyperplasia. 99mTc­MIBI scan is an important method of preoperative diagnosis, but only in combination with other radiological methods in case of the defeat of 2 or more parathyroid glands.

Article Details

How to Cite
Lishchynski, P., V. Palamarchuk, O. Nechay, M. Urina, O. Tovkay, and V. Kutz. “Laboratory and Instrumental Criteria for Assessing the Persistence of Primary Hyperparathyroidism Within the First Day After Surgery. Retrospective Assessment of Risk”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 15, no. 4, Feb. 2019, pp. 283-9, doi:10.22141/2224-0721.15.4.2019.174813.
Original Researches


Gouveia S, Rodrigues D, Barros L, et al. Persistent primary hyperparathyroidism: an uncommon location for an ectopic gland – case report and review. Arq Bras Endocrinol Metabol. 2012;56(6):393-403.

Demıralay E, Altaca G, Demırhan B. Morphological evaluation of parathyroid adenomas and immunohistochemical analysis of PCNA and ki-67 proliferation markers. Turk Patoloji Derg. 2011;27(3):215-20. doi: 10.5146/tjpath.2011.01078.

Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Cohen J, Gierlowski TC, Schneider AB. A prospective study of hyperparathyroidism in individuals exposed to radiation in childhood. JAMA. 1990;264(5):581-4.

Wheeler MH. Primary hyperparathyroidism: A surgical perspective. Endocrinol Metab Clin North Am. 1989 Sep;18(3):701-14.

The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons position statement on the diagnosis and management of primary hyperparathyroidism. Endocr Pract. 2005;11(1):49-54. doi: 10.4158/EP.11.1.49.

Untch BR, Adam MA, Scheri RP, et al. Surgeon-performed ultrasound is superior to 99Tc-sestamibi scanning to localize parathyroid adenomas in patients with primary hyperparathyroidism: results in 516 patients over 10 years. J Am Coll Surg. 2011 Apr;212(4):522-9; discussion 529-31. doi: 10.1016/j.jamcollsurg.2010.12.038.

Farmer PE, Kim JY. Surgery and global health: A view from beyond the OR. World J Surg. 2008 Apr;32(4):533-6. doi: 10.1007/s00268-008-9525-9.

Velázquez-Fernández D, Laurell C, Saqui-Salces M, Pantoja JP, Candanedo-Gonzalez F, Reza-Albarrán A, et al. Differential RNAexpression profile by cDNA microarray in sporadic primary hyperparathyroidism (pHPT): Primary parathyroid hyperplasia versus adenoma. World J Surg. 2006 May;30(5):705-13. doi: 10.1007/s00268-005-0708-3.

Amin AL, Wang TS, Wade TJ, Yen TW. Normal PTH levels in primary hyperparathyroidism: Still the same disease? Ann Surg Oncol. 2011 Nov;18(12):3437-42. doi: 10.1245/s10434-011-1744-x.

Moretz WH 3rd, Watts TL, Virgin FW Jr, Chin E, Gourin CG, Terris DJ. Correlation of intraoperative parathyroid hormone levels with parathyroid gland size. Laryngoscope. 2007 Nov;117(11):1957-60. doi: 10.1097/MLG.0b013e31813c14fc.

Low RA, Katz AD. Parathyroidectomy via bilateral cervical exploration: a retrospective review of 866 cases. Head Neck. 1998;20(7):583-7.

Witteveen JE, Kievit J, Morreau H, Romijnand JA, Hamdy NAT. No recurrence of sporadic primary hyperparathyroidism when cure is established 6 months after parathyroidectomy. Eur J Endocrinol. 2010 Feb;162(2):399-406. doi: 10.1530/EJE-09-0789.

Nawrot I, Chudziński W, Ciąćka T, Barczyński M, Szmidt J. Reoperations for persistent or recurrent primary hyperparathyroidism: results of a retrospective cohort study at a tertiary referral center. Med Sci Monit. 2014;20:1604-12. doi: 10.12659/MSM.890983.

García-Talavera P, González ML, Aís G, et al. SPECT-CT in the localization of an ectopic retropharyngeal parathyroid adenoma as a cause for persistent primary hyperparathyroidism. Rev Esp Med Nucl Imagen Mol. 2012;31(5):275-7. doi: 10.1016/j.remn.2012.02.005.

Palamarchuk VA, Tovkay AA, Voytenko VV, Mazur OV, Nechay AP. Modern approach to parathyroid cancer: etiology, pathogenesis, diagnosis, treatment. Clinical Endocrinology and Endocrine Surgery. 2019;1(65):7-17. doi: 10.30978/CEES-2019-1-7. (in Russian).

Marcheix B, Brouchet L, Berjaud J, Dahan M. Recurrent hyperparathyroidism: a sixth mediastinal parathyroid gland. Eur J Cardiothorac Surg. 2006 Nov;30(5):808-10. doi: 10.1016/j.ejcts.2006.07.030.

Shen W, Düren M, Morita E, et al. Reoperation for persistent or recurrent primary hyperparathyroidism. Arch Surg. 1996;131(8):861-7; discussion 867-9. DOI: 10.1001/archsurg.1996.01430200071013.

Wells SA, Debenedetti MK, Doherty GM. Recurrent or persistent hyperparathyroidism. J Bone Miner Res. 2002 Nov;17 Suppl 2:N158-62.

Voytenko VV, Palamarchuk VO. Asymptomatic primary hyperparathyroidism. Clinic, diagnosis, treatment (clinical case). Clinical Endocrinology and Endocrine Surgery. 2018;4(64):80. doi: 10.24026/1818-1384.4(64).2018.150029. (in Ukrainian).

Urina MO, Palamarchuk VO. Methodology of 4D computed tomography in diagnosis of pathologically changed parathyroid glands in patients with primary hyperparathyroidism. Ukrainian Journal of Pediatric Endocrinology. 2018;(27-28):39-44. doi: 10.30978/UJPE2018-3-4-39. (in Ukrainian).